Yuva Biosciences

Yuva Biosciences is a biotechnology company that leverages artificial intelligence to address aging and age-related diseases by targeting mitochondrial health. The company developed a proprietary AI platform called MitoNova™, which is designed to predict biologically active compounds that improve mitochondrial function. This platform integrates diverse biological, chemical, and mitochondrial datasets, utilizing an iterative feedback loop between computational predictions and wet-lab experimental validation. By focusing on mitochondrial restoration, the company aims to develop therapeutic and natural candidates that impact various biological processes, including those associated with skin, hair, and reproductive health.

The company’s research has led to the development of proprietary bioactive ingredients, such as Y100, which are designed to reverse visible signs of aging and are available for licensing to partners in the cosmetic and personal care industries. Yuva Biosciences has successfully transitioned from academic research at the University of Alabama at Birmingham (UAB) to commercial application, evidenced by partnerships with companies like BosleyMD to integrate its technology into consumer wellness products. Beyond aesthetics, the company is actively expanding its research into therapeutic areas such as ovarian aging, cardiometabolic diseases, and obesity, supported by grants and partnerships focused on developing AI-powered therapies.